P021
P021 | CNTF-Derived Neurogenic Peptide
DoseGear research brief
P21 is a nootropic peptide derived from ciliary neurotrophic factor (CNTF) that enhances neurogenesis and cognitive function. It contains an adamantane moiety that enables blood-brain barrier penetration. Research shows it increases BDNF expression, inhibits LIF signaling to promote neurogenesis, and reduces tau and amyloid pathology in Alzheimer's disease models. Remarkably, P21 can boost neurogenesis in diseased brains above levels seen in healthy untreated brains.
P21 operates through multiple pathways: it inhibits leukemia inhibitory factor (LIF) signaling, removing a key roadblock to neurogenesis and shifting the brain toward a more embryologic state favoring neuron growth. It increases brain-derived neurotrophic factor (BDNF) expression and activates the BDNF/TrkB/PI3-K/AKT/GSK3β pathway. This pathway modulation improves cognitive function and reduces tau and amyloid pathologies.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Synthetic peptide associated with CNTF-derived neurotrophic research.
Preclinical cognition and neurogenesis research with proposed neurotrophic and BDNF-associated effects.
Not reported in the reviewed compound-specific evidence.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
P021 Treatment in 3xTg-AD Mice
P21 and BDNF/TrkB Pathway
P21 in Cognitive Aging
P21 as Promising AD Drug Candidate
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
